{
    "clinical_study": {
        "@rank": "78854", 
        "arm_group": {
            "arm_group_label": "BIND-014", 
            "arm_group_type": "Experimental"
        }, 
        "brief_summary": {
            "textblock": "The purpose of this study is to evaluate the efficacy and safety BIND-014 in patients with\n      metastatic castration-resistant prostate cancer (mCRPC)."
        }, 
        "brief_title": "A Phase 2 Study to Determine the Safety and Efficacy of BIND-014 (Docetaxel Nanoparticles for Injectable Suspension), Administered to Patients With Metastatic Castration-Resistant Prostate Cancer", 
        "completion_date": {
            "#text": "December 2015", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "CRPC", 
            "Prostate Cancer"
        ], 
        "condition_browse": {
            "mesh_term": "Prostatic Neoplasms"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Histologically or cytologically confirmed adenocarcinoma of the prostate\n\n          -  Metastatic disease progressing despite castrate levels of testosterone\n\n          -  Prostate cancer progression documented by PSA\n\n          -  Surgically or medically castrated, with testosterone levels of < 50 ng/dL\n\n          -  Previous anti-androgen therapy and progression after withdrawal\n\n          -  ECOG performance status of 0 to 1\n\n          -  Adequate organ function\n\n          -  Prior radiation therapy allowed to < 25% of the bone marrow\n\n          -  Prior hormonal therapy is allowed\n\n          -  Patient compliance and geographic proximity that allow adequate follow-up.\n\n          -  Patients with reproductive potential must use contraceptive methods\n\n          -  Signed informed consent from patient\n\n        Exclusion Criteria:\n\n          -  Active infection\n\n          -  Any chronic medical condition requiring a high doses of corticosteroid\n\n          -  Pathological finding consistent with small cell carcinoma of the prostate\n\n          -  Brain metastasis\n\n          -  Prior cytotoxic chemotherapy or biologic therapy for the treatment of CRPC\n\n          -  Radiation therapy for treatment of the primary tumor within 6 weeks\n\n          -  Radionuclide therapy for treatment of metastatic CRPC\n\n          -  Prior systemic treatment with an azole drug\n\n          -  Prior flutamide treatment within 4 weeks\n\n          -  Prior bicalutamide or nilutamide within 6 weeks\n\n          -  Congenital long QT syndrome, congestive heart failure, or bradyarrhythmia\n\n          -  Administration of an investigational therapeutic within 2 weeks\n\n          -  Second primary malignancy\n\n          -  Presence of clinically detectable third-space fluid collections\n\n          -  History of severe hypersensitivity reaction to polysorbate 80\n\n          -  Peripheral neuropathy at study entry"
            }, 
            "gender": "Male", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "40", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "March 14, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01812746", 
            "org_study_id": "BIND-014-004"
        }, 
        "intervention": {
            "arm_group_label": "BIND-014", 
            "intervention_name": "BIND-014", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": "Docetaxel"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "February 18, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Los Angeles", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "90048"
                    }, 
                    "name": "Investigative Site #16"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "San Francisco", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "94115"
                    }, 
                    "name": "Investigative Site #14"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Fort Meyers", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "33908"
                    }, 
                    "name": "Investigative Site #17"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Ann Arbor", 
                        "country": "United States", 
                        "state": "Michigan", 
                        "zip": "48109"
                    }, 
                    "name": "Investigational Site #12"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "New York", 
                        "country": "United States", 
                        "state": "New York", 
                        "zip": "10065"
                    }, 
                    "name": "Investigational Site #11"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Chapel Hill", 
                        "country": "United States", 
                        "state": "North Carolina", 
                        "zip": "27514"
                    }, 
                    "name": "Investigational Site #15"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Cleveland", 
                        "country": "United States", 
                        "state": "Ohio", 
                        "zip": "44195"
                    }, 
                    "name": "Investigational Site #13"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Nashville", 
                        "country": "United States", 
                        "state": "Tennessee", 
                        "zip": "37203"
                    }, 
                    "name": "Investigational Site #18"
                }
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "An Open Label, Multicenter, Phase 2 Study to Determine the Safety and Efficacy of BIND-014 (Docetaxel Nanoparticles for Injectable Suspension), Administered to Patients With Metastatic Castration-Resistant Prostate Cancer", 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "August 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Number of patients with a progression-free survival of 6 months", 
            "measure": "To determine the efficacy of BIND-014 as measured by radiographic progression-free survival (rPFS) in patients with chemotherapy-na\u00efve metastatic CRPC", 
            "safety_issue": "No", 
            "time_frame": "Patients will be followed for the duration of treatment, an expected average of 24 weeks"
        }, 
        "reference": {
            "PMID": "22491949", 
            "citation": "Hrkach J, Von Hoff D, Mukkaram Ali M, Andrianova E, Auer J, Campbell T, De Witt D, Figa M, Figueiredo M, Horhota A, Low S, McDonnell K, Peeke E, Retnarajan B, Sabnis A, Schnipper E, Song JJ, Song YH, Summa J, Tompsett D, Troiano G, Van Geen Hoven T, Wright J, LoRusso P, Kantoff PW, Bander NH, Sweeney C, Farokhzad OC, Langer R, Zale S. Preclinical development and clinical translation of a PSMA-targeted docetaxel nanoparticle with a differentiated pharmacological profile. Sci Transl Med. 2012 Apr 4;4(128):128ra39. doi: 10.1126/scitranslmed.3003651."
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01812746"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "Number of patients who experience adverse events", 
            "measure": "To assess the safety and tolerability of BIND-014", 
            "safety_issue": "Yes", 
            "time_frame": "Patients will be followed for the duration of treatment, an expected average of 24 weeks"
        }, 
        "source": "BIND Therapeutics", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "BIND Therapeutics", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "April 2013", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "February 2014"
    }
}